By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Medical Device Network on MSN2d
Vivani Medical to spin-off neurostim business Cortigent as public companyVivani was created in 2022 when subdermal drug implant company Nano Precision Medical merged with implantable visual ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...
About Cortigent, Inc. Cortigent, Inc., formerly Second Sight Medical Products and a wholly owned subsidiary of Vivani, is developing brain implant devices to help people recover critical body ...
Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback